Lenalidomide Restores the Osteogenic Differentiation of Bone Marrow Mesenchymal Stem Cells from Multiple Myeloma Patients Via Deactivating Notch Signaling Pathway

Overview

Journal Oncotarget

Specialty Oncology

Date 2017 Sep 15

PMID 28903429

Citations 12

Authors

Juan Guo

Chengming Fei

Youshan Zhao

Sida Zhao

Qingqing Zheng

Jiying Su

Dong Wu

Xiao Li

Chunkang Chang

Affiliations

Soon will be listed here.

Abstract

Multiple myeloma (MM) always presents osteolytic bone lesions, resulting from the abnormal osteoblastic and osteoclastic function in patients. MM patients exhibit the impairment of osteogenic differentiation of BMMSCs (bone marrow mesenchymal stem cells) and osteoblast deficiency. Effects of the drug, lenalidomide on the osteoblastic functions and the involved mechanisms remain unexplored. In the present study, it is observed that the osteogenic differentiation of BMMSCs from MM patients (MM-MSCs) is impaired and activation of Notch signaling pathway in MM-MSCs is abnormal. Notch signaling activation inhibits BMMSCs osteogenesis. Knockdown of Notch1 expression and DAPT application reverse the osteogenic differentiation from MM-MSCs. Furthermore, it is shown that the gene expression of Notch signaling molecules, including receptors, ligands and downstream factors are significantly decreased in MM-MSCs following lenalidomide treatment, compared with non-treated MM-MSCs. Taken together, treatment with lenalidomide restores the osteogenic differentiation of MM-MSCs via deactivating Notch signaling pathway.

Citing Articles

A comprehensive review of oncogenic Notch signaling in multiple myeloma.

Roosma J PeerJ. 2024; 12:e18485.

PMID: 39619207 PMC: 11608568. DOI: 10.7717/peerj.18485.

DLK1 and DLK2, two non-canonical ligands of NOTCH receptors, differentially modulate the osteogenic differentiation of mesenchymal C3H10T1/2 cells.

Rodriguez-Cano M, Gonzalez-Gomez M, Monsalve E, Diaz-Guerra M, Kassem M, Laborda J Biol Res. 2024; 57(1):77.

PMID: 39473022 PMC: 11523663. DOI: 10.1186/s40659-024-00561-7.

Mesenchymal stromal cell senescence in haematological malignancies.

Plakhova N, Panagopoulos V, Vandyke K, Zannettino A, Mrozik K Cancer Metastasis Rev. 2023; 42(1):277-296.

PMID: 36622509 DOI: 10.1007/s10555-022-10069-9.

Inhibiting PI3K-AKT-mTOR Signaling in Multiple Myeloma-Associated Mesenchymal Stem Cells Impedes the Proliferation of Multiple Myeloma Cells.

Heinemann L, Mollers K, Ahmed H, Wei L, Sun K, Nimmagadda S Front Oncol. 2022; 12:874325.

PMID: 35795041 PMC: 9251191. DOI: 10.3389/fonc.2022.874325.

Lenalidomide improves HO-induced PC12 cell injury by blocking the Notch signaling pathway.

Lv Z, Yin S, Cheng Z, Wang K Exp Ther Med. 2022; 23(6):421.

PMID: 35601070 PMC: 9117949. DOI: 10.3892/etm.2022.11348.

References

Breitkreutz I, Raab M, Vallet S, Hideshima T, Raje N, Mitsiades C . Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma. Leukemia. 2008; 22(10):1925-32. DOI: 10.1038/leu.2008.174. View

Arnulf B, Lecourt S, Soulier J, Ternaux B, Lacassagne M, Crinquette A . Phenotypic and functional characterization of bone marrow mesenchymal stem cells derived from patients with multiple myeloma. Leukemia. 2006; 21(1):158-63. DOI: 10.1038/sj.leu.2404466. View

. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003; 121(5):749-57. View

Munemasa S, Sakai A, Kuroda Y, Okikawa Y, Katayama Y, Asaoku H . Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation. Int J Oncol. 2008; 33(1):129-36. View

Zhao Y, Wu D, Fei C, Guo J, Gu S, Zhu Y . Down-regulation of Dicer1 promotes cellular senescence and decreases the differentiation and stem cell-supporting capacities of mesenchymal stromal cells in patients with myelodysplastic syndrome. Haematologica. 2014; 100(2):194-204. PMC: 4803146. DOI: 10.3324/haematol.2014.109769. View

Reagan M, Ghobrial I . Multiple myeloma mesenchymal stem cells: characterization, origin, and tumor-promoting effects. Clin Cancer Res. 2011; 18(2):342-9. PMC: 3261316. DOI: 10.1158/1078-0432.CCR-11-2212. View

Kuci S, Kuci Z, Kreyenberg H, Deak E, Putsch K, Huenecke S . CD271 antigen defines a subset of multipotent stromal cells with immunosuppressive and lymphohematopoietic engraftment-promoting properties. Haematologica. 2010; 95(4):651-9. PMC: 2857196. DOI: 10.3324/haematol.2009.015065. View

Xu S, Evans H, Buckle C, De Veirman K, Hu J, Xu D . Impaired osteogenic differentiation of mesenchymal stem cells derived from multiple myeloma patients is associated with a blockade in the deactivation of the Notch signaling pathway. Leukemia. 2012; 26(12):2546-9. DOI: 10.1038/leu.2012.126. View

Ghazanfari R, Li H, Zacharaki D, Lim H, Scheding S . Human Non-Hematopoietic CD271/CD140a Bone Marrow Stroma Cells Fulfill Stringent Stem Cell Criteria in Serial Transplantations. Stem Cells Dev. 2016; 25(21):1652-1658. PMC: 5098131. DOI: 10.1089/scd.2016.0169. View

10.

Hideshima T, Chauhan D, Shima Y, Raje N, Davies F, Tai Y . Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood. 2000; 96(9):2943-50. View

11.

Hilton M, Tu X, Wu X, Bai S, Zhao H, Kobayashi T . Notch signaling maintains bone marrow mesenchymal progenitors by suppressing osteoblast differentiation. Nat Med. 2008; 14(3):306-14. PMC: 2740725. DOI: 10.1038/nm1716. View

12.

Kuci Z, Seiberth J, Latifi-Pupovci H, Wehner S, Stein S, Grez M . Clonal analysis of multipotent stromal cells derived from CD271+ bone marrow mononuclear cells: functional heterogeneity and different mechanisms of allosuppression. Haematologica. 2013; 98(10):1609-16. PMC: 3789467. DOI: 10.3324/haematol.2013.092700. View

13.

Chiba S . Notch signaling in stem cell systems. Stem Cells. 2006; 24(11):2437-47. DOI: 10.1634/stemcells.2005-0661. View

14.

Noll J, Williams S, Tong C, Wang H, Quach J, Purton L . Myeloma plasma cells alter the bone marrow microenvironment by stimulating the proliferation of mesenchymal stromal cells. Haematologica. 2013; 99(1):163-71. PMC: 4007935. DOI: 10.3324/haematol.2013.090977. View

15.

Pennisi A, Li X, Ling W, Khan S, Zangari M, Yaccoby S . The proteasome inhibitor, bortezomib suppresses primary myeloma and stimulates bone formation in myelomatous and nonmyelomatous bones in vivo. Am J Hematol. 2008; 84(1):6-14. PMC: 2612734. DOI: 10.1002/ajh.21310. View

16.

Artavanis-Tsakonas S, Rand M, Lake R . Notch signaling: cell fate control and signal integration in development. Science. 1999; 284(5415):770-6. DOI: 10.1126/science.284.5415.770. View

17.

Canalis E, Adams D, Boskey A, Parker K, Kranz L, Zanotti S . Notch signaling in osteocytes differentially regulates cancellous and cortical bone remodeling. J Biol Chem. 2013; 288(35):25614-25625. PMC: 3757222. DOI: 10.1074/jbc.M113.470492. View

18.

Zanotti S, Smerdel-Ramoya A, Stadmeyer L, Durant D, Radtke F, Canalis E . Notch inhibits osteoblast differentiation and causes osteopenia. Endocrinology. 2008; 149(8):3890-9. PMC: 2488209. DOI: 10.1210/en.2008-0140. View

19.

Pellagatti A, Jadersten M, Forsblom A, Cattan H, Christensson B, Emanuelsson E . Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci U S A. 2007; 104(27):11406-11. PMC: 1892786. DOI: 10.1073/pnas.0610477104. View

20.

Fei C, Zhao Y, Gu S, Guo J, Zhang X, Li X . Impaired osteogenic differentiation of mesenchymal stem cells derived from bone marrow of patients with lower-risk myelodysplastic syndromes. Tumour Biol. 2014; 35(5):4307-16. DOI: 10.1007/s13277-013-1565-6. View